Emerging indications for permanent pacing

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

New indications for pacing are being investigated in the areas of vasovagal syncope, hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, and atrial fibrillation. It is hoped that pacing will offer an alternative therapy to patients who are refractory to medical therapy. Although pacing for vasovagal syncope continues to be controversial, it appears that a highly symptomatic group with a predominately cardioinhibitory component can benefit. Current data indicate that dual-chamber pacing should not be considered therapeutically equal to septal myectomy in patients with hypertrophic obstructive cardiomyopathy, but may be considered in those more than 65 years of age, or in others who are not good surgical candidates. Biventricular or left ventricular pacing appears promising in heart failure patients and may be combined with implantable cardioverter- defibrillator therapy. Lead technology for coronary vein placement needs further improvement. Dual-site atrial pacing appears to help prevent recurrences of atrial fibrillation and may become a useful adjunct to drug, ablative, and implantable cardioverter-defibrillator therapies.

Original languageEnglish (US)
Pages (from-to)353-360
Number of pages8
JournalCurrent Cardiology Reports
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2000

Fingerprint

Vasovagal Syncope
Implantable Defibrillators
Hypertrophic Cardiomyopathy
Atrial Fibrillation
Dilated Cardiomyopathy
Complementary Therapies
Coronary Vessels
Therapeutics
Heart Failure
Technology
Recurrence
Pharmaceutical Preparations
Lead

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{ffe711162cf642f2aaeaa20ed4f62fe9,
title = "Emerging indications for permanent pacing",
abstract = "New indications for pacing are being investigated in the areas of vasovagal syncope, hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, and atrial fibrillation. It is hoped that pacing will offer an alternative therapy to patients who are refractory to medical therapy. Although pacing for vasovagal syncope continues to be controversial, it appears that a highly symptomatic group with a predominately cardioinhibitory component can benefit. Current data indicate that dual-chamber pacing should not be considered therapeutically equal to septal myectomy in patients with hypertrophic obstructive cardiomyopathy, but may be considered in those more than 65 years of age, or in others who are not good surgical candidates. Biventricular or left ventricular pacing appears promising in heart failure patients and may be combined with implantable cardioverter- defibrillator therapy. Lead technology for coronary vein placement needs further improvement. Dual-site atrial pacing appears to help prevent recurrences of atrial fibrillation and may become a useful adjunct to drug, ablative, and implantable cardioverter-defibrillator therapies.",
author = "Deborah Wolbrette and Gerald Naccarelli",
year = "2000",
month = "12",
day = "1",
doi = "10.1007/s11886-000-0093-3",
language = "English (US)",
volume = "2",
pages = "353--360",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

Emerging indications for permanent pacing. / Wolbrette, Deborah; Naccarelli, Gerald.

In: Current Cardiology Reports, Vol. 2, No. 4, 01.12.2000, p. 353-360.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Emerging indications for permanent pacing

AU - Wolbrette, Deborah

AU - Naccarelli, Gerald

PY - 2000/12/1

Y1 - 2000/12/1

N2 - New indications for pacing are being investigated in the areas of vasovagal syncope, hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, and atrial fibrillation. It is hoped that pacing will offer an alternative therapy to patients who are refractory to medical therapy. Although pacing for vasovagal syncope continues to be controversial, it appears that a highly symptomatic group with a predominately cardioinhibitory component can benefit. Current data indicate that dual-chamber pacing should not be considered therapeutically equal to septal myectomy in patients with hypertrophic obstructive cardiomyopathy, but may be considered in those more than 65 years of age, or in others who are not good surgical candidates. Biventricular or left ventricular pacing appears promising in heart failure patients and may be combined with implantable cardioverter- defibrillator therapy. Lead technology for coronary vein placement needs further improvement. Dual-site atrial pacing appears to help prevent recurrences of atrial fibrillation and may become a useful adjunct to drug, ablative, and implantable cardioverter-defibrillator therapies.

AB - New indications for pacing are being investigated in the areas of vasovagal syncope, hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, and atrial fibrillation. It is hoped that pacing will offer an alternative therapy to patients who are refractory to medical therapy. Although pacing for vasovagal syncope continues to be controversial, it appears that a highly symptomatic group with a predominately cardioinhibitory component can benefit. Current data indicate that dual-chamber pacing should not be considered therapeutically equal to septal myectomy in patients with hypertrophic obstructive cardiomyopathy, but may be considered in those more than 65 years of age, or in others who are not good surgical candidates. Biventricular or left ventricular pacing appears promising in heart failure patients and may be combined with implantable cardioverter- defibrillator therapy. Lead technology for coronary vein placement needs further improvement. Dual-site atrial pacing appears to help prevent recurrences of atrial fibrillation and may become a useful adjunct to drug, ablative, and implantable cardioverter-defibrillator therapies.

UR - http://www.scopus.com/inward/record.url?scp=0034220036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034220036&partnerID=8YFLogxK

U2 - 10.1007/s11886-000-0093-3

DO - 10.1007/s11886-000-0093-3

M3 - Article

VL - 2

SP - 353

EP - 360

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

ER -